G R Haenen Selected Research

7-monohydroxyethylrutoside

12/2011	Differences in pharmacological activities of the antioxidant flavonoid monoHER in humans and mice are caused by variations in its metabolic profile.
5/2001	Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity.
4/2000	7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

G R Haenen Research Topics

Disease

5	Cardiotoxicity 12/2011 - 04/2000
2	Inflammation (Inflammations) 09/2016 - 03/2001
1	Carcinogenesis 09/2016
1	Neoplasms (Cancer) 05/2001
1	Rheumatoid Arthritis 03/2001
1	Asthma (Bronchial Asthma) 03/2001
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 03/2001
1	Sarcoidosis (Schaumann Disease) 03/2001
1	Heart Diseases (Heart Disease) 11/2000
1	Infertility (Sterility) 11/2000
1	Pulmonary Emphysema 06/2000
1	Emphysema 06/2000
1	Heart Failure 04/2000

Drug/Important Bio-Agent (IBA)

5	FlavonoidsIBA 12/2011 - 04/2000
4	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2011 - 04/2000
3	7-monohydroxyethylrutosideIBA 12/2011 - 04/2000
1	Benzo(a)pyreneIBA 09/2016
1	CarcinogensIBA 09/2016
1	GlucuronidaseIBA 09/2016
1	AnthracyclinesIBA 12/2011
1	frederineIBA 05/2001
1	NF-kappa B (NF-kB)IBA 03/2001
1	Proteins (Proteins, Gene)FDA Link 03/2001
1	Pharmaceutical PreparationsIBA 11/2000
1	TeaIBA 11/2000
1	AntioxidantsIBA 11/2000
1	Glutathione (Reduced Glutathione)IBA 06/2000
1	Antineoplastic Agents (Antineoplastics)IBA 04/2000
1	HydroxyethylrutosideIBA 04/2000

Therapy/Procedure

1	Aftercare (After-Treatment) 11/2000
1	Therapeutics 11/2000